ABSTRACT
Background Accurate identification of brain tumour molecular subgroups is increasingly important. We aimed to establish the most accurate and reproducible ependymoma subgroup biomarker detection techniques, across 147 cases from International Society of Pediatric Oncology (SIOP) Ependymoma II trial participants, enrolled in the pan-European “Biomarkers of Ependymoma in Children and Adolescents (BIOMECA)” study.
Methods Across six European BIOMECA laboratories we evaluated epigenetic profiling (DNA methylation array); immunohistochemistry (IHC) for nuclear p65-RELA, H3K27me3, and Tenascin-C; copy number analysis via FISH and MLPA (1q, CDKN2A), and MIP and DNA methylation array (genome-wide copy number evaluation); analysis of ZFTA- and YAP1-fusions by RT-PCR and sequencing, Nanostring and break-apart FISH.
Results DNA Methylation profiling classified 65.3% (n=96/147) of cases as EPN-PFA and 15% (n=22/147) as ST-ZFTA fusion-positive. Immunohistochemical loss of H3K27me3 was a reproducible and accurate surrogate marker for EPN-PFA (sensitivity 99-100% across three centres). IHC for p65-RELA, FISH, and RNA-based analyses effectively identified ZFTA- and YAP1- fused supratentorial ependymomas. Detection of 1q gain using FISH exhibited only 57% inter-centre concordance and low sensitivity and specificity whilst MIP, MLPA and DNA methylation-based approaches demonstrated greater accuracy.
Conclusions We confirm, in a prospective trial cohort, that H3K27me3 immunohistochemistry is a robust EPN-PFA biomarker. Tenascin-C should be abandoned as a PFA marker. DNA methylation and MIP arrays are effective tools for copy number analysis of 1q gain, 6q and CDKN2A loss whilst FISH is inadequate. Fusion detection was successful, but rare novel fusions need more extensive technologies. Finally, we propose test sets to guide future diagnostic approaches.
Key points We evaluated and cross-validated ependymoma biomarkers in a large prospective clinical trial cohort.
Accurate biomarker evaluation is critical to the success of clinical trials and patient care.
We propose core and core+ biomarker test sets for future molecular stratification.
Importance of the Study High-risk paediatric ependymoma has a poor prognosis and is devastating at relapse. Molecularly defined ependymoma types need to be accurately and reliably linked to biomarkers to predict clinical outcomes and design clinical trials. Here, we evaluated and cross-validated ependymoma biomarkers in a large prospective clinical trial cohort highlighting the importance of systematic evaluation of different methods. We provide evidence to guide test selection to support the molecular stratification of paediatric ependymoma and deliver insights into the rationalisation of biomarkers for use in resource-limited settings.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT 02265770
Clinical Protocols
https://www.frontiersin.org/articles/10.3389/fneur.2022.887544/full
Funding Statement
The SIOP Ependymoma II clinical trial is funded in the UK by Cancer Research UK. The BIOMECA study is funded by Children with Cancer UK.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Nottingham 2 Research Ethics Committee of the National Health Service Health Research Authority (HRA) gave ethical approval for this work. The research ethics committee reference is 15/EM/0103.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
On Behalf of the Biomarkers of Ependymoma in Childhood and Adolescence (BIOMECA) Consortium.
Conflict of interest The authors declare no conflict of interest
AUTHORSHIP Experimental design: RJC, FA, FG, JG, CH, JPK, PB, MM, HW, PM, TP, PV, RGG, KWP, TAR
Implementation: RJC, FA, FB, ATE, CH, PM, TP, PV, HW, SMLP, IS, TJ, TAR
Data analysis: RJC, DRG, TAR, VZ, FA, SMLP, ATE, CH, PM, PV, MS
Data interpretation: RJC, DRG, TAR, RGG, TP, KWP
Manuscript preparation: RJC, TAR, DRG, RGG, TP, KWP
Data Availability
All data produced in the present study are available upon reasonable request to the authors